RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

The problem was that the two early partnerships, with Servier and Organon, were indication-based, regardless of the compound in question. So Cortex could not outlicense a later compound for neurodegeneration, schizophrenia, or depression. Big chunks of territory unavailable to a licensee. That's different from outlicensing specific molecules for a specific indication(s), which is the usual industry practice. It's highly unlikely they can outlicense CX1739 to two different partners for two different indications (e.g. ADHD and SA), but if they can, more power to them. That does not cede control of their other compounds.

<<I've long advocated for an across-the-board low-impact outlicencing strategy, in exchange for good upfronts and royalties. This would stabilize corx's bottom line, and would allow it to focus on high-impact development>>

If someone wanted to do this, maybe it's worth looking at. But that has not been the pattern in BP partnering, I'm at a loss to think of a deal where a BP licensed an entire CNS platform for all indications--do you know of one?

NeuroInvestment